The first commercial U.S. patient has received the Cartiva Synthetic Cartilage Implant (SCI) following its FDA Premarket Approval. SCI is intended for use in the treatment of great toe arthritis.
SCI presents an alternative to fusion, the current standard of care for this indication.
The first commercial U.S. patient has received the Cartiva Synthetic Cartilage Implant (SCI) following its FDA Premarket Approval. SCI is intended for use in the treatment of great toe arthritis.
SCI presents an alternative to fusion, the...
The first commercial U.S. patient has received the Cartiva Synthetic Cartilage Implant (SCI) following its FDA Premarket Approval. SCI is intended for use in the treatment of great toe arthritis.
SCI presents an alternative to fusion, the current standard of care for this indication.
Copy to clipboard 
